Abstract:Abstract Background While the COVID-19 pandemic seemed far from the end, the booster vaccine project was proposed to further reduce the transmission risk and infections. However, handful studies have focused on questions that with limited vaccine capacity ether boosting high-risk workers first or prioritizing susceptible normal individuals is optimal, and vaccinating how many people can lead us to the goal of herd immunity. In this study we aimed to explore the conclusions of such two problems with consideration of non-pharmacological interventions including mandatory quarantine for international entrants, keeping social distance and wearing masks. Methods By implementing the corresponding proportion of individuals who remain infectious after four lengths of quarantine strategies to the novel population-stratified model, we quantified the impact of such measures on optimizing vaccine prioritization between high-risk workers and normal populations. Furthermore, by setting the hypothetical COVID-19 transmission severity (reproduction number, R 0 ) to the level of the most contagious COVID-19 variant (B.1.617.2, delta variant, R 0 = 5.0), we separately estimated the threshold vaccine coverage of five countries (China, United States, India, South Africa and Brazil) to reach herd immunity, with and without the consideration of interventions including wearings masks and keeping social distance. At last, the sensitive analysis of essential parameter settings was performed to examine the robustness of conclusions. Results For Chinese scenarios considered with moderate hypothetical transmission rate ( R 0 = 1.15–1.8), prioritizing high-risk workers the booster dose reached lower cumulative infections and deaths if at least 7-days of quarantine for international travelers is maintained, and the required screening time to remain such vaccinating strategy as optimal increased from 7-days to 21-days with the transmission severity. Although simply maintaining at least 7-days quarantine can lead to over 69.12% reduction in total infections, the improvement of longer quarantine strategies was becoming minimum and the least one was 2.28% between the 21 and the 28-days of quarantine. Besides, without the vaccination program, the impact of such measures on transmission control dropped significantly when R 0 exceeded 1.5 and reached its minimal level when R 0 equal to 2.5. On the other hand, when we combat the delta variant, the threshold vaccine coverage of total population to reach herd immunity lay within 74%–89% (corresponding to the vaccine efficiency from 70% to 50%), and such range decreased to 71%–84% if interventions including wearing mask and keeping social distance were implemented. Furthermore, Results of other countries with 85% vaccine efficiency were estimated at 79%, 91%, 94% and 96% for South Africa, Brazil, India and United States respectively. Conclusions Non-pharmacological interventions can substantially affect booster vaccination prioritization and the threshold condition to reach herd immunity. To combat the delta variant, restrictions need to be integrated with mass vaccination so that can reduce the transmission to the minimum level, and the 21-days might be the suggested maximum quarantine duration according to the cost-effectiveness. Besides, by implementing interventions, the requirement to reach herd immunity can be lower in all countries. Lastly, the following surveillance after vaccination can help ensure the real-time proportion of vaccinated individuals with sufficient protection.

Predictive Efficacies of Vaccine Dose Fractionation Using Neutralizing Antibody Levels

Testing fractional doses of COVID-19 vaccines

Cost Effectiveness of Fractional Doses of COVID-19 Vaccine Boosters in India.

Could Vaccine Dose Stretching Reduce COVID-19 Deaths?

Comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India: a modelling study

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint

Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial

Efficacy of SARS-CoV-2 Vaccines and the Dose–response Relationship with Three Major Antibodies: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

Modeling how antibody responses may determine the efficacy of COVID-19 vaccines

Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2

Impact of non-pharmacological interventions on COVID-19 boosting vaccine prioritization and vaccine-induced herd immunity: a population-stratified modelling study

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection

Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers

Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk

Considerations for the Feasibility of Neutralizing Antibodies As a Surrogate Endpoint for COVID-19 Vaccines

Enhanced Neutralization of SARS-CoV-2 by a Tetravalent COVID-19 Vaccine Booster

Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine